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TRAP1 downregulation in human ovarian cancer
enhances invasion and epithelial–mesenchymal
transition
Maria R Amoroso1,6, Danilo S Matassa1,6, Ilenia Agliarulo1, Rosario Avolio1, Haonan Lu2, Lorenza Sisinni3, Giacomo Lettini3,
Hani Gabra4, Matteo Landriscina*,3,5 and Franca Esposito*,1
Ovarian cancer (OC) is the second leading cause of gynecological cancer death worldwide. Although the list of biomarkers is still
growing, molecular mechanisms involved in OC development and progression remain elusive. We recently demonstrated that
lower expression of the molecular chaperone TRAP1 in OC patients correlates with higher tumor grade and stage, and platinum
resistance. Herein we show that TRAP1 is often deleted in high-grade serous OC patients (N= 579), and that TRAP1 expression is
correlated with the copy number, suggesting this could be one of the driving mechanisms for the loss of TRAP1 expression in OC.
At molecular level, downregulation of TRAP1 associates with higher expression of p70S6K, a kinase frequently active in OC with
emerging roles in cell migration and tumor metastasis. Indeed, TRAP1 silencing in different OC cells induces upregulation of
p70S6K expression and activity, enhancement of cell motility and epithelial–mesenchymal transition (EMT). Consistently, in a large
cohort of OC patients, TRAP1 expression is reduced in tumor metastases and directly correlates with the epithelial marker
E-Cadherin, whereas it inversely correlates with the transcription factor Slug and the matrix metallopeptidases 2 and 9. Strikingly,
pharmacological inhibition of p70S6K reverts the high motility phenotype of TRAP1 knock-down cells. However, although p70S6K
inhibition or silencing reduces the expression of the transcription factors Snail and Slug, thus inducing upregulation of E-Cadherin
expression, it is unable to revert EMT induced by TRAP1 silencing; furthermore, p70S6K did not show any significant correlation
with EMT genes in patients, nor with overall survival or tumor stage, suggesting an independent and predominant role for TRAP1
in OC progression. Altogether, these results may provide novel approaches in OC with reduced TRAP1 expression, which could be
resistant to therapeutic strategies based on the inhibition of the p70S6K pathway, with potential future intervention in OC invasion
and metastasis.
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Epithelial ovarian cancer (OC) is the second leading cause of
gynecological cancer death in developed countries, account-
ing for 4% of deaths of cancer in women.1 OC is considered a
chemoresponsive neoplasm, with initial response rates to
systemic chemotherapy, exceeding 80% when integrated with
primary cytoreductive surgery.2 Despite this, the majority of
patients achieving a complete response with front-line
chemotherapy ultimately develop recurrent disease, with over
50% of women diagnosed with OC eventually dying from their
disease within 5 years from diagnosis.3 Data from major trials
report that the median progression-free survival for patients
with advanced disease ranges between 16 and 23 months,
while the median overall survival lies between 31 and 65
months.4 In this context, progresses in understanding the
intricate molecular mechanisms driving OC progression are
crucial. Among these, the PI3K/Akt and mTOR/p70S6K
pathway is frequently deregulated in OC.5 More specifically,
PIK3CA, the gene encoding the p110a catalytic subunit of
PI3K, is increased in copy number in 40% of OC;6 AKT1 and
AKT2 are both activated in a large number of OC, with the
activation being associated with high-grade tumors and
aggressive clinical behavior;7 constitutive activation of
p70S6K occurs significantly more often in malignant OC than
in benign or borderline lesions.8 In addition, recent findings
show that p70S6K may be involved in several aspects of OC
progression, including invasion and metastasis 9,10 and
epithelial–mesenchymal transition (EMT), through the induc-
tion of Snail,11 a transcriptional factor that, in turn, along with
other members of the same family such as Slug,12 regulates
the expression of molecules involved in cell adhesion and
invasion, such as E-Cadherin and thematrix metallopeptidase
2 (MMP2) and 9 (MMP9).13 Finally, it has been shown that
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p70S6K is a critical regulator of the actin cytoskeleton in the
acquisition of themetastatic phenotype and its depletion or the
inhibition of its activity reduced migration.14 These observa-
tions suggest a significant role for p70S6K inOC. Notably, AKT
and p70S6K undergo translational regulation by TRAP1 in
colorectal cancers 15,16 and such regulation affects cell
migration in HEK293 cells,16 in which TRAP1 knock-down
yields a higher migratory potential. Although current literature
mainly agrees that TRAP1 activity has important implications
for neoplastic progression,17 data from the different groups
only partially overlap, suggesting that TRAP1 may have
complex and possibly contextual effects on tumorigenesis.18
In fact, TRAP1 has an important role in the progression from a
localized to a metastatic disease19 and lower TRAP1 levels
correlated with increased overall survival20 in colorectal
cancers, whereas high TRAP1 expression correlates signifi-
cantly with favorable chemotherapy response and longer
overall survival in OC.21 Consistently, we have recently shown
that TRAP1 expression inversely correlates with grade and
stage and directly correlates with survival in a large cohort of
OC patients, and that low TRAP1 in OC cells and tissues
associated with a metabolic shift, ultimately causing the onset
of resistance to cisplatin-based chemotherapy.22 Herein, we
show that TRAP1 is often deleted in high-grade serous OC
and that TRAP1 expression is correlated with the copy
number. This can be one of the mechanisms for the
downregulation of TRAP1 in higher stage patients, with
consequent selection of drug resistant cells. Remarkably,
TRAP1 expression is inversely correlated with p70S6K
expression and phosphorylation and with genes involved in
EMT, thus affecting migration of OC cells and contributing to
the acquisition of metastatic phenotype in OC.
Results
Loss of TRAP1 expression in OC is due to genetic
deletion. Recent findings demonstrate that TRAP1 expres-
sion has a positive impact on response to therapy and
survival of patients in OC.21,22 To uncover possible mechan-
isms involved in the decreased TRAP1 levels in higher grade
tumors, we analyzed The Cancer Genome Atlas (TCGA)
database and found that there is a high percentage of TRAP1
deletion events in high-grade serous OC (Figure 1a) and that
TRAP1 expression is correlated with the copy number
(Figure 1b). The association between TRAP1 deletion and
loss of TRAP1 gene expression suggests that these deletion
events, even if 'shallow deletion' (see Materials and Methods
for further definition), are enough to have phenotypic effect.
Of note, owing to the threshold used, most gene-level copy
number variations (CNVs) in high-grade serous OC are
actually defined as 'shallow deletion'. Indeed, extensive
CNVs are not infrequent in these tumors; however, the
association between copy number of TRAP1 and its gene
expression suggests this could be one of the driving
mechanisms of TRAP1 decrease in OC. These data further
support and back up our previous findings showing that
TRAP1 expression inversely correlates with grade and stage
in OC,22 and provide a step forward on the role of TRAP1 in
OC progression.
TRAP1 level is correlated with lower p70S6K. To analyze
functional consequences of altered TRAP1 expression in
cancer models, we further characterized our previous
observations showing reduced protein expression and phos-
phorylation of p70S6K in high TRAP1 background in human
colorectal cancer cells and tissues.15 PI3K/AKT/p70S6K
Figure 1 TRAP1 loss of expression in OC. According to data from the TCGA data set, TRAP1 is often deleted in HGSOC (a) and TRAP1 expression is correlated with the
copy number (b) both conditions could account for the downregulation of TRAP1 in higher stage patients, suggesting a possible driver mechanism for TRAP1 loss of
expression in OC
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pathway is frequently activated in human OC, in which TRAP1
has a role in response to therapy and disease progression.22
Therefore, starting from these findings, we investigated the
role of TRAP1 in the regulation of the p70S6K in OC. Results
show that siRNA-mediated silencing of TRAP1 leads to
increased expression and phosphorylation levels of p70S6K
in three different human OC cell lines (PEA1, PEO1 and
PEO14) (Figure 2a). To exclude off-target effect, a second
Figure 2 TRAP1 level is correlated with lower p70S6K. (a) Total lysates obtained from PEA1, PEO1 and PEO14 cells were separated by SDS-PAGE and immunoblotted with
the indicated antibodies. Images are representative of three independent experiments. (b) Real-time RT-PCR analysis of p70S6K mRNAs expression in PEA1, PEO1 and PEO14
cells upon siRNA-mediated TRAP1 silencing. Data are expressed as mean±S.E.M. from three independent experiments with technical triplicate each. Numbers above bars
indicate the statistical significance (P-value), based on the two-tailed Student’s t-test. Dashed line indicate expression level of the relative control siRNA-transfected cells. (c)
PEA1 cells were transfected for 60 h with nontargeting control siRNA or TRAP1-directed siRNA, pulse labeled for 1 h as described in Materials and methods and chased for the
indicated times. Immunoprecipitates (IP) were analyzed by autoradiography and WB. (d and e) Correlation between TRAP1 mRNA expression and phospho-p70S6K(Thr389) (d)
and p70S6K protein expression (e). Statistical analysis by Spearman's rank correlation coefficient
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TRAP1 siRNA sequence was used in PEA1 cells, with
consistent results (Supplementary Figure 1). qPCR analyses
demonstrate that this regulation occurs at a post-
transcriptional level, being the mRNA levels not significantly
changed upon TRAP1 silencing in the same cell lines
(Figure 2b). To further investigate on this regulation, pulse-
chase experiments have been performed and show that
TRAP1 expression does not affect protein stability as well,
whereas a translational regulation is observed (Figure 2c): in
fact, p70S6K is already increased in TRAP1-silenced
PEA1 cells after 1 h of pulse labeling with radioactive Met/
Cys, and such difference is conserved through 3-h chase, as
confirmed by detectable signals only in TRAP1-silenced cells.
This is consistent with our previous results, showing that
TRAP1 exerts a co-translational protein quality control on its
substrates.23 Remarkably, TRAP1 mRNA level significantly
correlated with lower phospho-p70S6K (pT389) in a large
data set of OC specimens24 (Figure 2d). Interestingly,
although weak, an inverse correlation between TRAP1
expression and p70S6K protein levels is also present in
patients (Figure 2e). To exclude the possibility that p70S6K
could contribute to such inverse correlation by reciprocally
regulating TRAP1, we verified TRAP1 expression following
p70S6K silencing or treatment with the specific inhibitor
PF4708671.25 Data show that neither TRAP1 protein
(Supplementary Figures 2A and B) nor mRNA expression
(Supplementary Figure 2C) are influenced by p70S6K
inhibition or siRNA-mediated silencing.
TRAP1 inversely correlates with OC cell motility. Con-
sidering the involvement of TRAP1 in cell migration,16,26 and
the functional role played by p70S6K, especially in OC,
through the control of actin cytoskeleton dynamics,14 we
analyzed the migratory behavior of OC cells upon TRAP1
silencing. Wound-healing assays performed in PEA1 OC
cells demonstrated that TRAP1 silencing significantly
enhances (linear regression F=4.33; P=0.05) cell motility
(Figures 3a and b): in fact, PEA1 cells transfected with
TRAP1-directed siRNAs (Figure 3b, solid gray line) migrate
faster than their control siRNA-transfected counterpart
(Figure 3b, solid black line). To dissect the role of the
p70S6K upregulation consequent to TRAP1 silencing, we
treated either control or TRAP1-silenced cells, with the
specific p70S6K inhibitor PF4708671.25 Results show that
the treatment significantly reduces (linear regression
F=72.83; Po0.01) the rate of edge advancement of
TRAP1-silenced PEA1 cells (Figure 3b, dashed gray line),
whereas does not significantly (linear regression F= 0.53;
P=0.47) reduce the rate of edge advancement of control
cells (Figure 3b, dashed black line), thus leveling off the two
migration rates. To exclude off-target effects, the same
experiments was performed with a different TRAP1-directed
siRNA sequence, yielding similar results (Supplementary
Figure 3). As demonstrated in other experimental systems,16
treatment with LY294002, a PI3K inhibitor, markedly reduces
wound-healing progression in both TRAP1-silenced cells
(Supplementary Figure 3B, dotted gray line) and control cells
(Supplementary Figure 3B, dotted black line), thus confirming
the critical role played by PI3K in the regulation of cell motility
in both control and TRAP1-interfered cells.16 The significant
reduction of phospho-(active) p70S6K confirms the efficacy
of both treatments (Supplementary Figure 3C). In parallel
experiments, transwell migration assays confirmed that
TRAP1 silencing in OC cells enhances cell motility in a
p70S6K-dependent manner (Supplementary Figure 4).
These results are consistent with those found in other cell
lines, linking TRAP1 role in cell metabolism and migratory
capacity.27
TRAP1 is inversely correlated with EMT genes. Cell
motility is an important determinant of cancer invasive
potential: therefore, we asked whether TRAP1 expression is
linked to tumor progression in OC patients. Based on the data
of OC tissue biopsies, we analyzed TRAP1 levels in relation
to cancer site: results show that low TRAP1 expression is
mainly found in peritoneal biopsies localized at distant sites
from the primary tumors (Figure 4a). This suggests that
TRAP1 low expressing cancers may be more prone to spread
and disseminate from the primary site. For this behavior, a
key role is played by the activation of EMT gene expression
program, which is traditionally considered as a determinant of
tumorigenic and metastatic capacity in many cancer types.28
Therefore, to confirm a direct role for TRAP1 in regulating the
expression of key genes involved in EMT, we analyzed by
qPCR: (i) the epithelial marker E-Cadherin, (ii) the two major
transcription factors controlling E-Cadherin expression (Snail
and Slug/Snai2) and (iii) MMP2 and MMP9, two proteins that
are also upregulated in EMTand enable invasion and wound
healing.29 We found that siRNA-mediated silencing of TRAP1
in PEA1 cells leads to upregulation of Snail1, Slug, MMP2
and MMP9 and to downregulation of E-Cadherin expression
(Figure 4b). In vivo relevance of our observations was
confirmed by the analysis of TRAP1-related EMT program
in our reference database: according to in vitro data, we
found that lower TRAP1 expression is directly correlated to
E-CADHERIN protein levels (Figure 4c) and inversely
correlated to Slug/Snai2 (Figure 4d), MMP2 (Figure 4e) and
MMP9 (Figure 4f) mRNA levels, thus indicating increased
invasive potential. Immunoblot analyses performed in
PEA1 cells upon TRAP1 silencing confirmed that TRAP1
and E-CADHERIN protein levels are directly correlated
(Figure 4g).
p70S6K is an EMT inducer in OC. Our experiments have
shown that TRAP1 downmodulation simultaneously leads to
p70S6K upregulation and EMT activation; we then ques-
tioned whether p70S6K could be directly involved in such
regulations, as it has been previously shown that p70S6K
induced Snail expression in OC cells.11 To address this issue,
we treated PEA1 cells with the selective p70S6K inhibitor
PF4708671 and analyzed the mRNA levels of E-Cadherin,
MMP9, Snail and Slug by qPCR, 3 and 24 h after treatment.
Figure 5 shows that p70S6K inhibition results in early
downregulation of the transcription factors Snail and Slug
(Figure 5a), with a consequent increase of E-CadherinmRNA
levels at later times (Figure 5b), confirming the role of
p70S6K in EMT of these cells. Immunoblots show the
significant upregulation of E-CADHERIN protein expression
following p70S6K inhibition, which is confirmed by the loss of
phosphorylation of the p70S6K target rpS6 (Figure 5c).
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siRNA-mediated p70S6K silencing yielded similar results
(Supplementary Figure 5). Consequently, we performed
p70S6K inhibition following siRNA-mediated TRAP1 silen-
cing (Figure 5d). As a result, p70S6K inhibition was less
effective in modulating the expression of Snail, Slug and
E-Cadherin in TRAP1-silenced cells compared with controls;
even increasing concentrations of PF4708671 up to 40 μM
was not sufficient to revert EMT induced by TRAP1 silencing
(Figure 5e). All the PF4708671 concentration used are
subtoxic (Supplementary Figure 6). Considering that TRAP1
is upstream p70S6K in their regulation (Figure 1;
Supplementary Figure 2), as demonstrated by the absence
of TRAP1 regulation upon p70S6K inhibition or silencing
(Supplementary Figure 2), these data suggest that EMT
regulation in OC is a very complex process in which the
contribution of more than one factor and pathway is
necessary. The above findings suggest a possible novel
clinical implication, that is, OC with reduced TRAP1 expres-
sion could be resistant to therapeutic strategies based on the
inhibition of the p70S6K pathway. In keeping with this
conclusion, we found that, as opposed to TRAP1, p70S6K
expression does not have any impact on overall survival
(Figure 6a) and there is no correlation between tumor stage
and p70S6K mRNA (Figure 6b), protein (Figure 6c) or
phosphoprotein (Figure 6d). Accordingly, p70S6K mRNA
expression does not correlate with expression of either Snail,
E-Cadherin, MMP2 and MMP9 in a large database of patients
(Figure 7a); moreover, the positive correlation between
p70S6K and Slug mRNA expression is lost when p70S6K
protein levels are analyzed (Figure 7b). These observations
question the relevance of p70S6K expression/activity in the
pathophysiology of OC progression and malignancy, whereas
strengthening the importance of TRAP1 as a prognostic
marker in this system.
Discussion
Despite extensive effort, at present survival rates of patients
with OC remain poor and OC continues to be a poorly
understood disease.30 Recent reports have underlined some
peculiarities of OC cells at a molecular level, especially linked
to metabolic regulations.31,32 Intriguingly, the molecular
chaperone TRAP1 has a dominant role in this system: TRAP1
has long been considered uniformly oncogenic in a variety of
cancer types,17 whereas it inversely correlates with OC stage
and grade 22 and has a positive impact on patients’ survival
and response to therapy.21 A substantial amount of evidence
suggests that the molecular functions exerted by TRAP1 are
Figure 3 TRAP1 affects cell migration through p70S6K. (a and b) Time-lapse acquisition of untreated and PF4708671-treated PEA1 cells transfected for 72 h with non-
targeted control siRNA or TRAP1-directed siRNA, immediately after the wound (t0) and after 6 h (t6h). Scale bar, 500 μm. The rate of advancement, evaluated as the difference
between empty space at each time point, is reported as a function of time in (b) for cells transfected with control siRNA (black) and TRAP1-directed siRNA (gray). Dashed lines
are used for PF4708671-treated cultures, solid lines for untreated cultures. Data are expressed as mean±S.E.M. from three independent experiments. Lines have been fitted
with linear regression
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conserved in a variety of cell models and are not limited to a
specific cellular context, for example, regulating the expres-
sion of the oncogene BRAF 33 and the calcium-binding protein
Sorcin 34,35 in both colorectal and breast cancers. Conversely,
the effect of such regulations on tumor development and
progression are dependent on tumor context. In fact, TRAP1
silencing increases oxidative phosphorylation in several cell
lines,22,27,36 leading to impaired oncogenic potential in
osteosarcoma cells,36 but to more aggressive phenotype
and chemoresistance in OC (Matassa et al.;22 this study). As
such, some data show that higher TRAP1 expression reduces
cell motility,16,37 but also increases metastasis in prostate 26
and colorectal 16 cancers, and confers resistance to conditions
normally impairing cell migration.15,16 Accordingly, in this
study we show that an inverse correlation between TRAP1
and p70S6K previously found in colorectal cancer is con-
served in OC cells and patients, and that this correlation
affects cell migration, resulting in increased motility of cells
with low TRAP1/high p70S6K levels. Pharmacological sup-
pression of p70S6K significantly decreases cell migration,
abolishing the increased motility of TRAP1 knock-down cells.
Cell migration is considered a prerequisite of tumor
invasion, but the latter is a complex phenomenon, in which
multiple environmental conditions and regulatory mechan-
isms, such as EMT, are involved. EMT is defined as a
functional transition of polarized epithelial cells into mesench-
ymal cells able to migrate and to secrete components of the
extracellular matrix. Carcinoma cells undergoing this transi-
tion may induce disease progression by invading and
metastasizing.28 For this reason, we investigated EMT
in vitro, upon TRAP1 silencing, and ex vivo, by correlating
expression of TRAP1 and EMT markers in high-grade serous
OCpatients. Consistently, lowTRAP1 correlated with changes
in the expression of genes commonly associated to EMT;
accordingly, TRAP1 levels were higher in primary tumor sites
than in the peritoneum deposits of advanced diseases and
accumulating evidence show that p70S6K could have multiple
roles in invasion and metastasis in OC. Thus, depletion of
p70S6K inOC cells decreases cell migration,38 with significant
inhibition of actin cytoskeleton reorganization,14 but p70S6K is
also involved in EMT activation, via repression of E-cadherin
through the upregulation of Snail;11 p70S6K has also recently
been proposed as a regulator for the seeding and successful
Figure 4 Lower TRAP1 expression is associated with more advanced disease and EMT. (a) Correlation between TRAP1 mRNA expression and tumor sample site from the
Tothill data set (P-values determined by the Wilcoxon rank sum test). (b) Real-time RT-PCR analysis of SNAIL, SNAI2/SLUG, SNAIL3, MMP9, MMP2 and E-Cadherin expression
in PEA1 cells 72 h after transfection with non-targeted control siRNA or TRAP1-directed siRNA. Data are expressed as mean± S.E.M. from three independent experiments with
technical triplicate each. Numbers above bars indicate the statistical significance (P-value), based on one-sample t-test. Dashed line indicate expression level of the relative
control siRNA-transfected cells. (c) Correlation between TRAP1 mRNA expression and E-CADHERIN protein expression. Statistical analysis by Spearman's rank correlation
coefficient. (d–f) Correlation between TRAP1 mRNA expression and SLUG/SNAI2 (d), MMP2 (e) and MMP9 (f) mRNA expression. Statistical analysis by Pearson's product
moment correlation coefficient. (g) Total lysates obtained from PEA1 cells transfected for 72 h with non-targeted control siRNA or TRAP1-directed siRNAwere separated by SDS-
PAGE and immunoblotted with the indicated antibodies. Numbers indicate densitometric band intensities, calculated by assuming protein levels of the control equal 1. Images are
representative of three independent experiments
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colonization of OC spheroids on the peritoneum.39 Accord-
ingly, in our cell models, selective inhibition of p70S6K was
able to regulate the expression of EMT genes, showing a
function reciprocal to that exerted by TRAP1. Besides,
inhibition of p70S6K in TRAP1-silenced cells, expressing
higher levels of p70S6K, is not effective in reversing EMT. One
of the most relevant result in this study is the absence of
correlation of p70S6K and TRAP1 in EMT: differently from the
regulation of cell migratory capacity by these two proteins, the
obtained results suggest that TRAP1 downmodulation triggers
EMT, at least in part, through mechanisms, which are
independent from the p70S6K pathway. As a result, in this
specific database, p70S6K overexpression seems to be
dispensable for the progression of OC, finally displaying no
impact on patient survival, advancement of disease and, at a
molecular level, expression of genes involved in invasion
and EMT.
Notably, albeit EMT is commonly believed to contribute to
metastasis, recent studies report that it is conversely
dispensable for metastasis and rather contribute to resistance
to chemotherapy.40,41 Our recent results showing that down-
regulation of TRAP1 induces drug resistance in OC cells
through metabolic remodeling are in keeping with these
data.22 More interestingly, our findings suggest a possible
novel clinical implication/approach, that is, OC with reduced
TRAP1 expression could be resistant to therapeutic strategies
based on the inhibition of the p70S6K pathway. However, the
role of EMT in drug resistance of OC, although very interesting
and novel, will require further in depth studies.
Taken together, these observations support the hypothesis
that the metabolic phenotype of the tumor and the nutrient
availability in the surrounding microenvironment strongly
influence migratory and invasive properties in OC through a
modulation of TRAP1 and the expression/activity of p70S6K,
thus providing a step forward in the puzzling TRAP1-driven
pathophysiology in OC progression and malignancy.
Materials and Methods
CNV profiling. The CNV profile was collected by TCGA project for high-grade
serous OC patients. The gene-level CNV was estimated using the GISTIC2.0
method ('GISTIC2.0 facilitates sensitive and confident localization of the targets of
focal somatic copy number alteration in human cancers') and further thresholded
into homozygous deletion (deep deletion), single-copy deletion (shallow deletion),
diploid normal copy, low-level copy number amplification or high-level copy number
amplification.
Figure 5 p70S6K regulation of genes involved in EMT. (a and b) Real-time RT-PCR analysis of SNAIL, SNAI2/SLUG, MMP9 and E-Cadherin expression in PEA1 cells
treated with 20 μM PF4708671 for 3 h (a) or 24 h (b). Data are expressed as mean± S.E.M. from three independent experiments with technical triplicate each. Numbers above
bars indicate the statistical significance (P-value), based on one-sample t-test. Dashed line indicate expression level of the relative control siRNA-transfected cells. (c) PEA1 cells
were treated with 20 μM PF4708671 for 24 h, total lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. Numbers indicate densitometric band
intensities, calculated by assuming protein levels of the control equal 1. Images are representative of three independent experiments. (d and e) Real-time RT-PCR analysis of
SNAIL, SNAI2/SLUG and E-Cadherin expression in PEA1 cells treated with 20 μM (d) or 40 μM (e) PF4708671 for 3 h (SNAIL, SLUG analysis) or 24 h (E-Cadherin analysis),
following transfection with non-targeted control siRNA or TRAP1-directed siRNA. Data are expressed as mean± S.E.M. from three independent experiments with technical
triplicate each. Numbers above bars indicate the statistical significance (P-value), based on one-sample t-test. Dashed line indicate expression level of the relative untreated cells
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Cell cultures and treatments. The high-grade serous OC cell lines PEA1,
PEO1 and PEO14 have been described elsewhere.42 Cell line verification was
performed by Identifiler kit (Applied Biosystems-Thermo Fisher Scientific, Waltham,
MA, USA). All lines were maintained in RPMI 1640 media with 10% fetal bovine
serum, penicillin, streptomycin, glutamine at 37 °C/5% CO2. Cell lines are routinely
monitored in our laboratory by microscopic morphology check.
For wound-healing and gene expression experiments, cells were treated with the
selective p70S6K inhibitor PF4708671 (Santa Cruz Biotechnology, Dallas, TX, USA,
sc-361288), dissolved in DMSO.
Transfection procedures. TRAP1 transient silencing was performed with two
different siRNAs purchased from Qiagen (Milano, Italy): sense strand: 5′-CGG
UCCCUGUACUCAGAAATT-3′; antisense strand: 5′-UUUCUGAGUACAGGGACCG
GG-3′ (cat. no. SI00115150); sense strand: 5′-GCUACACCCUGCACUAUAATT-3′;
antisense strand: 5′-UUAUAGUGCAGGGUGUAGCGG-3′ (cat. no. SI00115164).
p70S6K transient silencing was performed with siRNAs purchased from Qiagen:
sense strand: 5′-GAGUUGGACCAUAUGAACUTT-3′; antisense strand: 5′-AGU
UCAUAUGGUCCAACUCCC-3′ (cat. no. SI00301721). For control experiments, cells
were transfected with a similar amount of nontargeting control siRNA (Qiagen; cat. no.
SI03650318). Transient transfections of siRNAs were performed using HiPerFect
Transfection Reagent (Qiagen) according to the manufacturer's protocol.
Western blot analysis. Equal amounts of protein from cell lysates were
subjected to SDS-PAGE and transferred to a PVDF membrane (Merck-Millipore,
Darmstadt, Germany). Where indicated, protein levels were quantified by
densitometric analysis using the software ImageJ.43 The following antibodies were
Figure 6 p70S6K expression does not have relevant roles in the advancement of disease. (a) Kaplan–Meier estimates of the impact of p70S6K on overall survival (P-values
determined by the log-rank test). (b-d) Correlation between p70S6K mRNA (b), protein (c) or phosphoprotein (d) and tumor stage from the TCGA data set (P-values determined
by the Kruskal–Wallis test)
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used: anti-TRAP1 (sc-13557), anti-β-actin (sc-69879) and anti-p70S6K (sc-230), from
Santa Cruz Biotechnology; anti-phospho p70 S6 kinase (Thr389) (#9205), anti-
E-Cadherin (#3195) and anti-phospho-S6 ribosomal protein (#2215) from Cell
Signaling Technology (Danvers, MA, USA).
RNA extraction and real-time RT-PCR. Total RNA extraction procedures
were performed by using TRI Reagent (Sigma-Aldrich, Milano, Italy, product code
T9424), following the manufacturer’s instruction. The following primers were used for
PCR analysis. TRAP1: forward 5′-GACGCACCGCTCAACAT-3′, reverse 5′-CA
CATCAAACATGGACGGTTT-3′; p70S6K: forward 5′-ACTTCTGGCTCGAAAGG
TGG-3′, reverse 5′-TTGAGTCATCTGGGCTGTCG-3′; ACTIN: forward 5′-
CCTCACCCTGAAGTACCCA-3′, reverse 5′-TCGTCCCAGTTGGTGACGAT-3′; E-
Cadherin: forward 5′-CAGCCTGTCGAAGCAGGATT-3′, reverse 5′-TCATCCTC
TGGGGGCAGTAA-3′;MMP9: forward 5′-TTCTACTGGCGCGTGAGTTC-3′, reverse
5′-GCACTGCAGGATGTCATAGGT-3′; MMP2: forward 5′-GCTACGATGGAGGC
GCTAAT-3′, reverse 5′-GGGCAGCCATAGAAGGTGTT-3′; Snail1: forward 5′-
CGAGTGGTTCTTCTGCGCTA-3′, reverse 5′-GGGCTGCTGGAAGGTAAACT-3′;
Slug: forward 5′-ACAGCGAACTGGACACACAT-3′, reverse 5′-GAGAGGCCATTGG
GTAGCTG-3′; Snail3: forward 5′-TGACTTATAGTGAGCACCGCC-3′, reverse 5′-A
CATAGACGTGTGACATGGGG-3′. When possible, primers were designed to be
intron spanning. The reaction conditions were 95 °C for 5 min followed by 45 cycles
of 15 s at 95 °C and 1 min at 60 °C. Actin was chosen as the internal control. In
PCR analyses performed upon TRAP1 silencing, RNAs were collected 72 h after
siRNA transfection.
Pulse chase. PEA1 cells were incubated in cysteine/methionine-free medium
(Sigma-Aldrich) for 30 min followed by incubation in cysteine/methionine-free medium
containing 50 μCi/ml 35S-labeled cysteine/methionine (GE Healthcare, Buckingham-
shire, UK) for 1 h. After labeling, cells were washed once with culture medium
containing excess of unlabeled methionine and cysteine (5 mM each) and incubated
further in the same medium. Cells were collected at the indicated time points and
lysates were immunoprecipitated with p70S6K antibodies (sc-230) and separated by
10% SDS-PAGE. Proteins were transferred onto a PVDF membrane and analyzed by
autoradiography. The same filters were then probed by western blot.
Wound-healing assay. In order to study the dynamics of wound closure,
cells were seeded in monolayer by plating in 12-well plates 2 × 105 cells per well in
complete medium; 24 h after plating the cell layer was scratched with sterile pipette
tip. Wound healing was followed for 6 h by acquiring digital frames at 2-h intervals
with an objective 10x (scale 0.767 pixel/μ). Quantitative analysis of wound invasion
by cell populations located at the border was performed by measuring the gap area,
which was defined by using the wand tool in ImageJ 43 and manually refining the
selection in the presence of gross errors. The rate of advancement, evaluated as the
difference between empty spaces at each time points, was reported as a function of
time. Images have been acquired by using the Leica AF6000 Modular System
equipped with a 10 × /0.22 objective, and captured by using the Leica LAS AF Lite
Software (Leica Microsystems, Milano, Italy). Where indicated, cells were pre-treated
with PF4708671 or placed in a glutamine-deprived medium 1 h before performing the
scratch.
Transwell migration assay. Migration was assayed using a modified Boyden
chamber (Corning Costar, Corning, NY, USA) containing a polycarbonate membrane
filter (6.5 mm diameter, 8 mm pore size) coated with poly-L-lysine. The upper
chamber contained cells in RPMI plus 1% FBS in the absence or presence of
PF4708671 (20 μM) and the lower chamber contained RPMI plus 10% FBS as a
chemoattractant. Cells were incubated for 18 h at 37 °C in 5% CO2. Non-migrated
cells were scraped off the upper surface of the membrane with a cotton swab.
Migrated cells remaining at the bottom surface were fixed with ethanol for 10 min 37 °
C and stained with crystal violet (0.5% in 25% methanol) for 10 min at room
temperature. Excess staining was washed off by rinsing in water. Staining was eluted
with 200 μl of 1% SDS and quantitated by spectrophotometric reading at 570 nm.
Statistics. Serous OC cases from Tothill data set (Affymetrix U133 plus2.0
microarray, Santa Clara, CA, USA, GSE9891) and TCGA data set (level 3 data, total
RNA sequencing and reverse phase protein array) were used to correlate TRAP1
mRNA expression with the expression of other genes. Wilcoxon rank sum test was
used to compare gene expression between two groups. Pearson's product moment
correlation coefficient was used to correlate the mRNA expression of two genes.
The paired Student’s t-test was used to establish the statistical significance of
differences between gene expression levels in qPCR.
Patients and study approval. Patients’ samples were collected under the
Imperial College London Tissue Bank project number R15024 (TRAP1 regulates
bioenergetics features, cisplatin resistance and EMT in OC) in accordance with the
Imperial College London guidelines. Express written informed consent to use
biological specimens for investigational procedures was obtained from all patients.
All experimental protocols were approved by Hammersmith and Queen Charlotte’s
and Chelsea Research Ethics Committee.
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